Date published: 2025-11-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

ARMC10 Inhibitors

ARMC10 inhibitors are a class of chemical compounds designed to specifically target and inhibit the function of the Armadillo repeat-containing 10 (ARMC10) protein. This protein has been implicated in various cellular processes, including those associated with mitochondrial dynamics and neuronal development. ARMC10 inhibitors achieve their function by binding to the active or allosteric sites of ARMC10, preventing it from participating in its normal roles within the cell. These inhibitors are precisely tailored to the unique structural aspects of ARMC10, ensuring that their interaction is highly specific, which minimizes off-target effects and enhances their inhibitory efficacy. As ARMC10 is believed to facilitate the assembly of protein complexes involved in mitochondrial fusion and fission, its inhibition can disrupt the delicate balance of mitochondrial dynamics, leading to a predominance of fission events. This can result in fragmented mitochondria, which may affect cellular energy metabolism and apoptosis pathways.

The design of ARMC10 inhibitors is grounded in an in-depth understanding of the protein's structure-activity relationship, which guides the selection of functional groups in the inhibitors that can maximize binding affinity and inhibitory potency. Inhibitors may act by mimicking the natural substrates or ligands of ARMC10, occupying its binding sites, or by inducing conformational changes that render the protein inactive. By blocking the function of ARMC10, these inhibitors can indirectly influence several downstream signaling pathways that are crucial for maintaining cellular homeostasis, particularly in neurons where ARMC10 has been found to play a significant role. The inhibition of ARMC10 can lead to alterations in the dynamics of the cytoskeleton and affect the trafficking of mitochondria along the neuronal axons, potentially impacting neuronal outgrowth and regeneration. As research progresses, the understanding of these inhibitors and their interaction with ARMC10 continues to deepen, shedding light on the molecular intricacies that govern the protein's involvement in cellular processes.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Rapamycin binds to FKBP12 and the resulting complex inhibits mTOR, a kinase that indirectly influences ARMC10 stabilization through the mTOR signaling pathway. Reduced mTOR activity decreases ARMC10-mediated signaling, leading to a reduction in its functional activities related to cell growth and proliferation.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

LY294002 is a potent inhibitor of PI3K, which acts upstream of mTOR. Inhibition of PI3K leads to a downregulation of the mTOR pathway, consequently reducing ARMC10 activity as it is a downstream effector within this signaling axis.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

Wortmannin is another PI3K inhibitor that acts similarly to LY294002, leading to a decrease in ARMC10 function by impeding the PI3K/AKT/mTOR signaling cascade, which is known to regulate this protein's activity.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

PD98059 inhibits MEK, which is part of the MAPK/ERK pathway. The MAPK/ERK pathway is implicated in the regulation of ARMC10 stability, and inhibition of this pathway would result in its decreased activity.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

SB203580 is an inhibitor of p38 MAPK, another kinase within the MAPK pathway. Inhibition of p38 MAPK can decrease ARMC10 activity by altering signaling events that stabilize or activate ARMC10.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

Inhibits JNK, a kinase in the MAPK pathway. JNK is involved in stress response and its inhibition can lead to reduced ARMC10 activity through indirect regulation of cellular processes that stabilize ARMC10.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$150.00
$920.00
5
(0)

Sunitinib is a receptor tyrosine kinase inhibitor that can indirectly decrease ARMC10 activity by inhibiting signaling pathways that contribute to the stabilization and activation of ARMC10.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$56.00
$260.00
$416.00
129
(3)

As a multikinase inhibitor, Sorafenib can decrease ARMC10 activity by inhibiting various pathways, including RAF/MEK/ERK, which indirectly affects ARMC10's function.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$112.00
$163.00
$928.00
19
(1)

Trametinib is a MEK inhibitor that reduces MAPK/ERK signaling, thereby potentially lowering ARMC10 activity by modulating the pathway that affects its stability and function.

Erlotinib, Free Base

183321-74-6sc-396113
sc-396113A
sc-396113B
sc-396113C
sc-396113D
500 mg
1 g
5 g
10 g
100 g
$85.00
$132.00
$287.00
$495.00
$3752.00
42
(0)

Erlotinib targets the EGFR tyrosine kinase, which is involved in pathways that can stabilize ARMC10. Inhibition of EGFR leads to a reduction in ARMC10 activity through downstream signaling events.